HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2001; **16**: 657–658.

Author Index

Altamura, C., 219
Anderer, P., 177
Andreasen, N. C., 273
Ansseau, M., 219, S31
Antun, F. P., 279
Arnaout, M. S., 279
Artigas, F., 29
Ashkar, K., 279
Averbuch, E., 333

Bagby R. M., 105
Baker, A., 481
Baker, R. W., 147
Baldwin, D. S., S93
Baumann, P., S85
Becker, S., 627
Begg, A., 475
Belmaker, R. H., 37
Belsham, B., 139
Ben-Abdallah, A., 599
Benjamin, J., 189, 237
Ben-Zion, I. Z., 189, 237
Bhaumik, S., 133
Biswas, A. B., 133
Bitter, I., 219
Blier, P., 23
Booij, J., 579
Bosch, F., 533
Botella, P., 533
Boulton, D. W., 541
Bourin, M., 9
Branford, D., 133
Brice, C., 507, 523
Buchanan, T., 619
Burrows, G. D., 541

Caldwell, J., S67, S105
Carlson, G. A., 257
Carr, E., 481
Cavallaro, R., 439
Center, B. A., 257
Chae, B.-J., 265
Clarke, J., 345
Clenet, F., 9
Cocchi, F., 439
Cockram, A. M., 423
Compton, W. M., 599
Costa e Silva, J. A., S31
Cottler, L. B., 599
Crea, F., 257
Creeley, C. E., 309

Dagens-Lafont, V., S39
Dalery, J., S39
Dannon, P., 189
Daumann, J., 627
de Bodinat, C., S39
De Risio, S., S31
De Vane, C. L., 541
den Heeten, G. J., 579
Dilling, H., S31
Dinan, T. G., 89, 293
Dodd, S., 541
Dong, J., 23
Downey, L., 345
Drummond, G., 475, 635

Eap, C. B., S85
Earle, J., 481
Eisfeld, B. S., 105
Eldar, S., 327
Ellingrod, V., 273
Erman, M. K., 169
Erwin, C. W., 169

Feinberg, I., 403
Figuera, M. L., 461
Fiocco, A. J., 9
Fleming, F. W., 273
Forza, G., 635
Fox, H. C., 613
Fux, M., 37

Gengo, F. M., 169
Gloria, R., 409
Gouzoulis-Mayfraank, E., 627
Graff, E., 333, 403
Greenberg, B. D., 237
Gruper, D., 403
Gutierrez, J. L. A., 219

Haddjeri, N., 23
Halaris, A., 65
Halikas, J. A., 257
Hansen, L., 495
Hartmans, H. L. A., 449
Hauer, C., 177
Heffernan, T. M., 339, 607, 619
Herrington, R., S31
Hindmarch, I., 159, 203, 369, S101
Horrobin, D. F., 45
Hutchison, C. W., 345
Hutchison, C., 481

Jameison, K., 293
Jamieson, A. O., 169
Jarvis, H., 607
Jones, M., 481
Judd, F. K., 423

Kang, B.-J., 265
Kelemen, W. L., 309
Kennedy, S. H., 105
Kleijn, H. J., 449
Kotler, M., 403
Kumari, V., 321

Lôo, H., S31
Lader, M., 219
Lamers, C. T. J., 393
Laor, N., 327
Lemmi, H., 169
Leonard, B. E., 1, S79
Lepine, J. P., 219
Levine, J., 37
Lieb, R., S21
Liechti, M. E., 589
Ling, J., 339, 607, 619
Lloyd, J., 345

Maeda, H., 469
Maes, M., 95
Maguire, K., 303
Mahowald, M. W., 169
Majoie, C. B. L. M., 579
Mandl, M., 177
Manzato, M., 439
McCall, L., 423
Meiri, G., 189, 237
Mester, R., 333, 403
Meyer, J. H., 105
Miller, F. E., 125
Mistretta, P., 439

Copyright © 2001 John Wiley & Sons, Ltd.

Morita, K., 469
Mundo, E., 461
Murphy, D. L., 237

Nahas, G. G., 247
Nathan, , P. J., 345, 481
Nechmad, A., 403
Nemeroff, C. B., 81
Nemets, B., 37
Nieciecki, M., 481
Norman, T. R., 541

O'brien, D., 81
Ofek, A., 189
Owens, M. J., 81

Palatnik, A., 189
Parra, A., 533
Parrott, A. C., 557, 613, 641
Parrott, A., 619
Patat, A., 159, 369
Paty, I., 159, 369
Paul, I. A., 71
Pearson, V. L., 257
Pelz, S., 627
Piletz, J. E., 65
Pinder, R. M., 53
Piterman, L., 423
Polich, J., 409

Ramaekers, J. G., 393
Regestein, Q. R., 169
Reneman, L., 579
Rigney, U., 159
Rodgers, J., 607, 619
Romero, F. J., 533
Roth, T., 169
Roth-Schechter, B., 169
Rouillon, F., 461
Rush, C. R., 147
Ruwe, F. J. L., 449

Saiz-Ruiz, J., S31
Saletu, B., 177
Saletu, M., 177
Saletu-Zyhlarz, G., 177
Samuel, E., 327
Sandler, M., 61
Sartorius, N., S1, S3
Scharf, M. B., 169
Schifano, F., 635
Schlapnikov, N., 403
Scholey, A. B., 339
Scholey, A. B., 607, 619
Schreiber, S., 189
Schultz, S. K., 273
Schuster, P., S21
Schweitzer, I., 303
Semler, B., 177
Sharma, T., 321
Sitsen, J. M. A., 449
Skelton, K. H., 81
Smeraldi, E., 439
Smith, A., 507, 523
Smulders, R. A., 449
Soar, K., 641
Soni, W., 321
Spivak, B., 333, 403
Stanley, N., 159
Stigler, M., 461
Stough, C., 345
Stough, C., 481
Szabo, S., 23

Tanaka, M., 469
Tiller, J., 303
Tiplady, B., 475
Toplis, A. S., 613
Toren, P., 327
Tsolaki, M., 417
Tuchtenhagen, F., 627
Tuckwell, V., 303
Turner, J. J. D., 613, 641

van den Brink, W., 579
van der Kolk, B. A., S49
van Praag, H. M., 3
Vaz-Serra, A., S31
Vered, Y., 333, 403
Vinokurow, S., 333
Vogel, G. W., 169
Vollenweider, F. X., 589

Wainer, I. W., S105
Wainer, I. W., S73
Waintraaaub, L., 219
Walsh, J. K., 169
Ware, J. C., 169
Weiss, M., 403
Weissman, M. M., 423
Weizman, A., 333, 403
Weizman, R., 327
Wheatley, D., 353
Wittchen, H.-U., S21
Wolmer, L., 327
Womack, S. B., 599

Yamada, S., 469
Yamauchi, K., 469
Yoran-Hegesh, R., 333

Copyright © 2001 John Wiley & Sons, Ltd.

HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2001; **16**: 659–660.

Keyword Index

3,4-methylenedioxymethamphetamine, 589
3-methoxy-4-hydroxyphenylglycol (MHPG), 469
5-HT_{1A}, 29
5-hydroxytryptamine (5-HT), 61
7TM receptor, 247
abuse, 599
accelerating, 125
acoustic startle reflex, 321
acute, 345
agitation, 417
agmatine, 65
Akathisia, 495
alcohol, 393
alertness, 523
alprazolam, 469
amygdala, S49
Animal models, 9
antidepressant, 71, 125, 541, S85, S93, S101
Antidepressant, 37
antidepressants, 9, 29, 53, 81, 95, 105, 203, 495
antipsychotics, 495
anxiety, 81, 189, 237, 469
anxiety-depressive disorder, S21
anxiolytic, 353
anxious symptoms, 219
arachidonic acid, 45
attention deficit hyperactivity disorder (ADHD), 333
attention, 293, 309, 409
AVLT, 613

Bacopa monniera, 345
benzodiazepine, 475
Benzodiazepines, 147
bipolar, 139
blood brain barrier, 247
brahmi, 345
brain lateralization, S49
brain-derived neurotrophic factor (BDNF), 61
bupropion, 65

caffeine, 309, 523, 533
Caffeine, 507
calcium, 71
cannabis, 607, 619, 627
carbohydrate-rich meal, 403
carbon dioxide, 237
central executive, 607
chiral HPLC, 541
chiral, S67, S73, S105
choice reaction time, 159
chronic mild stress, 9
cicosapentacnoic acid, 45
CIDI-SAM, 599
citalopram, S85, S93, S101
classification, S3, S21
clinical trials, 29
clomipramine, 461
clozapine, 265, 403
club drugs, 599
cocaine abuse, 257
cocaine treatment, 257
coenzyme-A, 45
coffee, 533
cognition, 345, 557
cognitive assessment, 409
cognitive failures, 607
cognitive functions, 369
combination, 37
combinatorial chemistry, 53
comorbidity, S21
confabulation, 613
cortisol, 89
CRF antagonists, 81
CRF, 81
critical flicker fusion, 159
cytochrome P_{450}, 449
cytochrome P450, 541
cytokines, 95

declarative memory, 293
delayed recall, 613
denosologization of psychiatric diagnosis, 3
dependence, 599
depression, 45, 53, 65, 71, 81, 89, 95, 133, 139, 203, 293, 423, S85, S93, S101
depressions diagnoses and biology, 3
depressive disorders, S3, S31, S39
diabetes, 265
diagnosis, S21
diagnostic heterogeneity functional brain imaging, 105
digit symbol substitution text, 159
divalproex, 257
docosahexacnoic acid, 45
dopa, 333
dopamine agonist, 177
driving, 393, 523
drug discovery, 53
drug prevention, 635
drug-drug interaction, 449
DTS, 303

ecstasy, 339, 557, 589, 599, 607, 613, 619, 627, 635, 641
efficacy, 105, S93
elderly, 417
enantiomer, S67, S79, S73, S85, S101, S105,
enuresis, 327
epidemiology, S21
errors, 475
escitalopram, S85, S93, S101
everyday memory, 619

fatigue, 523
first episode, 439
first night effect, 177
fluoxetine, 133
Fluoxetine, S31
fluvoxamine, 327, 461
forced swim, 9
functionalization of psychiatric diagnosis, 3

general practice, 423
Ginkgo biloba, 409
glucocorticoids, 293
glutamate, 139
glycemic peak delay, 265

haloperidol, 439
heart rate, 247
high throughout screening, 53
hippocampus, 293, S49
human, 589
humans, 147
hypermobility, 189
hypnotic therapy, 169
hypnotic, 369

Copyright © 2001 John Wiley & Sons, Ltd.

hypnotics, 147
hypothalamic-pituitary-adrenal axis, 89
imidazolines, 65
imidazopyridines, 147
immediate recall, 613
impaired glucose tolerance, 265
inositol, 37
insomnia, 169, 353
interlcukin-10, 95
Internet, 619
interpersonal counselling, 423
isomer, S105

joint instability, 189
joint, 189

kava, 353

learned helplessness, 9
learning disabilities, 133
lipid bilayer, 247

Major Depressive Disorder, 105
major depressive disorder, 219
marihuana, 247, 393
MCMI-II, 303
MDD, 303
MDMA, 339, 557, 579, 589, 599, 607, 627, 635
memory impairment, 339
memory, 147, 309, 369, 557
mental function, 475
mental retardation, 133
metamemory, 309
metergoline, 237
methadone, S79
mirtazapine, 449, 541
mode of action, 203
molecular transmission, 247
monoamine hypothesis, 203
monoamines, 61
mood disorders, S3
MRI, 579

negative symptoms, 439
nerve growth factor (NGF), 61
neuroleptic malignant syndrome, 279
neurotoxicity, 339, 557, 579
neurotrophins, 61
nitric oxide synthase, 71
NMDA, 139
N-methyl-D-asparate, 71
noradrcnaline, 61
noradrenaline, 237
norepinephrenine, 333

obsessive-compulsive disorder, 461
olanzapine, 279
olfactory bulbectomy, 9

paroxetine, 133, 219,, 449
pathophysiology, 203
perception, 409
performance, 147,, 309,, 507
periodic limb movement disorder, 177
personality, 303
PET, 579
pharmacodynamics, 369
pharmacokinetics, 247,, 449,, 541
pharmacology, 237,, 589
phenylalanine, 273
phospholipase A_2, 45
phospholipids, 45
pindolol, 29
placebo, S39
platelet, 65
pleasant sensory perception (PSP), 247
polydrug, 641
polysomnography, 177
prepulse inhibition, 321
problematic, 641
prospective memory, 339,, 607, 619
psychobiology, S49
psychomotor performance, 369
psychopathology, 627, 641
psychopharmacology, S49
psychosocial factors, 507
PTSD, S49

racemate, S105
rapid, 125
reaction time, 533
recall, 147
receptor, 139
receptors, 29,, 65
receptor-specific antidepressants, 3
recreational, 641
recurrence, S39
relapse prevention, 257
relapse, S39
review, 579
risperidone, 439
ropinirole, 177

saliva, 469, 507
saliva, 533
schizophrenia, 139, 273,, 321,, 403,, 439
SCL-90, 635
search, 393
sedative, 353
selective serotonin reuptake inhibitors, 29, 133
sensorimotor gating, 321
serotonin reuptake inhibitor, 461
serotonin, 29, 237, 327, 333, 403, 557, 627
serum valproic acid level, 257
sex differences, 533
short-term memory, 409
side effects, 133
SPECT, 579
SSRIs, S49
startle gating, 321
stereochemistry, S67, S79, S73, S85, S101, S105
stress, 81, 353
subjective sleep and awakening quality, 177
subthreshold, S21
suicide, 495
sustained attention, 523

tandospirone, 469
tardive dyskinesia, 273
temazepam, 169
THC, 247
thioridazine, S79
tianeptine, 219,, S31,, S39
tiapride, 417
time estimation, 533
tobacco smoking, 321
tolerability, S93
TPQ, 635
transacyiase, 45
treatment–emergent behaviour, 133
treatment, 439
triazolam, 147

valerian, 353
venlafaxine, 423
verticalization of psychiatric diagnosis, 3
visual, 393

web, 619

xenobiotics GPCR, 247

zaleplon, 159, 369
zolpidem, 147,, 159,, 169
zopiclone, S79

Copyright © 2001 John Wiley & Sons, Ltd.

CONTENTS

Volume 16 Issue Nos 1–8 and Supplements 1 and 2

HUMAN PSYCHOPHARMACOLOGY

Issue No.1 January 2001

ANTIDEPRESSANTS: DEVELOPMENTS FOR THE 21ST CENTURY

Editorial: **B. E. Leonard** . . . 1

Past Expectations, Present Disappointments, Future Hopes *or* Psychopathology as the Rate-Limiting Step of Progress in Psychopharmacology: **H. M. van Praag** . . . 3

How Valuable are Animal Models in Defining Antidepressant Activity? **M. Bourin, A. J. Fiocco** and **F. Clenet** . . . 9

Enhancement of Serotoninergic Function—A Sometimes Insufficient Cause of Antidepressant Action **P. Blier, N. Haddjeri, S. T. Szabo** and **J. Dong** . . . 23

Limitations to Enhancing the Speed of Onset of Antidepressants—Are Rapid Action Antidepressants Possible? **F. Artigas** . . . 29

Combination of Antidepressant Drugs: The Case of Inositol: **B. Nemets, M. Fux J. Levine** and **R. H. Belmaker** . . . 37

Phospholipid Metabolism and Depression: The Possible Roles of Phospholipase A_2 and Coenzyme A-Independent Transacylase: **D. F. Horrobin** . . . 45

On the Feasibility of Designing New Antidepressants: **R. M. Pinder** . . . 53

Neurotrophins: Possible Role in Anxiety and Affective Disorders: **M. Sandler** . . . 61

Imidazoline Receptors: Possible Involvement in the Pathophysiology and Treatment of Depression: **A. Halaris** and **J. E. Piletz** . . . 65

Antidepressant Activity and Calcium Signaling Cascades: **I. A. Paul** . . . 71

Are CRF Receptor Antagonists Potential Antidepressants? **D. O'Brien, K. H. Skelton, M. J. Owens** and **C. B. Nemeroff** . . . 81

Novel Approaches to the Treatment of Depression by Modulating the Hypothalamic-Pituitary-Adrenal Axis: **T. G. Dinan** . . . 89

The Immunoregulatory Effects of Antidepressants: **M. Maes** . . . 95

Antidepressants in Clinical Practice: Limitations of Assessment Methods and Drug Response: **S. H. Kennedy, B. S. Eisfeld, J. H. Meyer** and **R. M. Bagby** . . . 105

Depression and Practice Guidelines: **J. S. McIntyre** . . . 115

Current awareness . . . 119

Supplement No.1 January 2001

PROCEEDINGS

NEW UNDERSTANDING AND MANAGEMENT STRATEGIES IN THE FIELD OF DEPRESSIVE DISORDERS

Editors: I. Hindmarch and B. S. McEwen

Preface: **N. Sartorius** S1

Concepts of Depression: Sporadic Revolutions of Continuous Evolution: **N. Sartorius** S3

Stress and Hippocampal Plasticity: Implications for the Pathophysiology of Affective Disorders: **B. S. McEwen and A. M. Magarinos** S7

Comorbidity and Mixed Anxiety-depressive Disorder (MAD): Clinical Curiosity or Pathophysiological Need? **H. U. Wittchen, P. Schuster and R. Lieb** S21

Efficacy and Safety of Tianeptine in the Treatment of Depressive Disorders in Comparison with Fluoxetine: **H. Lôo, J. Saiz-Ruiz, J. A. Costa e Silva, M. Ansseau, R. Herrington, A. Vaz-Serra, H. Dilling and S. De Risio** S31

Efficacy of Tianeptine Vs Placebo in the Long-Term Treatment (16.5 Months) of Unipolar Major Recurrent Depression: **J. Dalery, v. Dagens-Lafont and C. de Bodinat** S39

The Psychobiology and Psychopharmacology of PTSD: **B. A. van der Kolk** S49

Published with the help of an unrestricted educational grant from SERVIER

Issue No.2 March 2001

Strategies for the Rapid Treatment of Depression: **F. E. Miller** 125

Treatment-Emergent Behavioural Side-Effects with Selective Serotonin Re-uptake Inhibitors in Adults with Learning Disabilities: **A. B. Biswas, S. Bhaumik and D. Branford** 133

Glutamate and its Role in Psychiatric Illness: **B. Belsham** 139

Zolpidem and Triazolam Interact Differentially with a Delay Interval on a Digit-Enter-and-Recall Task: **C. R. Rush and R. W. Baker** 147

Residual Effects of Zaleplon and Zolpidem Following Middle of the Night Administration Five Hours to One Hour before Awakening: **I. Hindmarch, A. Patat, N. Stanley, I. Paty and U. Rigney** 159

Comparative Efficacy of Zolpidem and Temazepam in Transient Insomnia: **M. K. Erman, C. W. Erwin, F. M. Gengo, A. O. Jamieson, H. Lemmi, M. W. Mahowald, Q. R. Regestein, T. Roth, B. Roth-Schechter, M. B. Scharf, G. W. Vogel, J. K. Walsh and J. Catesby Ware** 169

Sleep Laboratory Studies in Periodic Limb Movement Disorder (PLMD) as Compared with Normals and Acute Effects of Ropinirole: **M. Saletu, P. Anderer, B. Saletu, C. Hauer, M. Mandl, B. Semler and G. Saletu-Zyhlarz** 177

Lack of Association Between Joint Hyperlaxity and I: Panic Disorder and II: Reactivity to Carbon Dioxide in Healthy Volunteers: **J. Benjamin, I. Z. Ben-Zion, P. Dannon, S. Schreiber, G. Meiri, A. Ofek and A. Palatnik** 189

Letter to the Editor

Neuroprotective Effects of Low-Doses of Aspirin: **C. Persegani, P. Russo, E. Lugaresi, M. Nicolini and M. Torlini** 193

Book Reviews 195

Current awareness 197

Issue No.3 April 2001

Review

Expanding the Horizons of Depression: Beyond the Monoamine Hypothesis: **I. Hindmarch** 203

Research Articles

Tianeptine and Paroxetine in Major Depressive Disorder, with a Special Focus on the Anxious Component in Depression: An International, 6-Week Double-Blind Study: **J. P. Lepine, C. Altamura, M. Ansseau, J. L. A. Gutierrez, I. Bitter, M. Lader and L. Waintraub** 219

The Platelet as a Peripheral Marker in Psychiatric Illness: **H. Plein and M. Berk** 229

Influence of the Serotonin Antagonist, Metergoline, on the Anxiogenic Effects of Carbon Dioxide, and on Heart Rate and Neuroendocrine Measures, in Healthy Volunteers: **G. Meiri, I. Z. Ben-Zion, B. D. Greenberg, D. L. Murphy and J. Benjamin** 237

The Pharmacokinetics of THC in Fat and Brain: Resulting Functional Responses to Marihuana Smoking: **G. G. Nahas** 247

A Pilot, Open Clinical Study of Depakote in the Treatment of Cocaine Abuse: **J. A. Halikas, B. A. Center, V. L. Pearson, G. A. Carlson and F. Crea** 257

The Effect of Clozapine on Blood Glucose Metabolism: **B.-J. Chae and B.-J. Kang** 265

The Association Between Risk Factors for Tarvide Dyskinesia and Phenylalanine-Induced Abnormal Movements in Schizophrenia: **S. K. Schultz, V. Ellingrod, F. W. Fleming and N. C. Andreasen** . . . 273

Case Report

Neuroleptic Malignant Syndrome with Olanzapine Associated with Severe Hypernatremia: **M. Samir Arnaout, F. P. Antum and K. Ashhar** 279

Book Reviews 282

Current Awareness 287

Issue No.4 June 2001

Review

Glucocorticoids and Cognitive Function: From Physiology to Pathophysiology: **K. Jameison and T. G. Dinan** 293

Research Articles

Personality Pathology, Depression and HPA Axis Functioning: **I. Schweitzer, V. Tuckwell, K. Maguire and J. Tiller** 303

Caffeine (4mg/kg) Influences Sustained Attention and Delayed Free Recall but not Memory Predictions: **W. L. Kelemen and C. E. Creeley** 309

Influence of Cigarette Smoking on Prepulse Inhibition of the Acoustic Startle Response in Schizophrenia: **V. Kumari, W. Soni and T. Sharma** 321

Fluvoxamine is Ineffective in the Treatment of Enuresis in Children and Adolescents: An Open-Label Pilot Study: **P. Toren, S. Eldar, N. Laor, L. Wolmer, E. Samuel and R. Weizman** 327

The Influence of Three Months of Methylphenidate Treatment on Platelet-Poor Plasma Biogenic Amine Levels in Boys with Attention Deficit Hyperactivity Disorder: **B. Spivak, Y. Vered, R. Yoran-Hegesh, E. Graff, E. Averbuch, S. Vinokurow, A. Weizman and R. Mester** 333

Subjective Ratings of Prospective Memory Deficits in MDMA ('Ecstasy') Users: **T. M. Heffernan, J. Ling and A. B. Scholey** 339

The Acute Effects of an Extract of *Bacopa monniera* (Brahmi) on Cognitive Function in Healthy Normal Subjects: **P. J. Nathan, J. Clarke, J. Lloyd, C. W. Hutchinson, L. Downey and C. Stough** 345

Stress-Induced Insomnia Treated with Kava and Valerian: Singly and in Combination: **D. Wheatley** . . 353

Book Reviews 357

Current Awareness 363

Issue No.5 July 2001

Research Articles

Pharmacodynamic Profile of Zaleplon, a New Non-benzodiazepine Hypnotic Agent: **A. Patat, I. Paty and I. Hindmarch** 369

Visual Search and Urban City Driving under the Influence of Marijuana and Alcohol: **C. J. Lamers and J. G. Ramaekers** 393

Plasma Serotonin Response to Carbohydrate-rich Food in Chronic Schizophrenic Patients: Clozapine versus Classical Antipsychotic Agents: **Y. Vered, B. Spivak, A. Nechmad, N. Schlapnikov, E. Graff, I. Feinberg, D. Gruper, M. Weiss, M. Kotler, A. Weizman and R. Mester** 403

Cognitive Effects of a Ginkgo Biloba/Vinpocetine Compound in Normal Adults: Systematic Assessment of Perception, Attention and Memory: **J. Polich and R. Gloria** 409

Evaluation of Tiapride in Agitated Elderly Outpatients: An Open Study: **M. Tsolaki and the Tiapride Study Group** 417

A Comparative Study of Venlafaxine with a Focused Education and Psychotherapy Program versus Venlafaxine Alone in the Treatment of Depression in General Practice: **F. K. Judd, L. Piterman, A. M. Cockram, L. McCall and M. M. Weissman** 423

Book Reviews 429

Current Awareness 433

Issue No.6 August 2001

Research Articles

Differential Efficacy of Risperidone versus Haloperidol in Psychopathological Subtypes of Subchronic Schizophrenia: **R. Cavallaro, P. Mistretta, F. Cocchi, M. Manzato and E. Smeraldi** 439

Mirtazapine and Paroxetine: A Drug-Drug Interaction Study in Healthy Subjects: **F. J. L. Ruwe, R. A. Smulders, H. J. Kleijn, H. L. A. Hartmans and J. M. A. Sitsen** 449

Fluvoxamine in Obsessive-Compulsive Disorder: Similar Efficacy but Superior Tolerability in Comparison with Clomipramine: **E. Mundo, F. Rouillon, M. L. Figuera and M. Stigler** 461

Comparative Study of Short-term Anxiolytic Potency of Alprazolam and Tandospirone in Psychiatric Outpatients with Anxiety Disorders: K. **Yamauchi, S. Yamada, K. Morita, H. Maeda and M. Tanaka** . 469

Effects of Temazepam on Memory and Psychomotor Performance: A Dose-Response Study: **A. Begg, G. Drummond and B. Tiplady** 475

Letter to the Editor
Cholinergic Modulation of Cognitive Function in Healthy Subjects: Acute Effects of Donepezil, a Cholinesterase Inhibitor: **P. J. Nathan, A. Baker, E. Carr, J. Earle, M. Jones, M. Nieciecki, C. Hutchison and C. Stough** 481

Book Reviews 485

Current Awareness 489

Issue No.7 October 2001

Review
A Critical Review of Akathisia and its Possible Association with Suicidal Behaviour: **L. Hansen** 495

Research Articles
Caffeine Levels in Saliva: Associations with Psychosocial Factors and Behavioural Effects: **C. Brice and A. Smith** 507

The Effects of Caffeine on Simulated Driving, Subjective Alertness and Sustained Attention: **C. Brice and A. Smith** 523

Sex Differences in Estimation of Time Intervals and in Reaction Time are Removed by Moderate but not High Doses of Caffeine in Coffee: **P. Botella, F. Bosch, F. J. Romero and A. Parra** 533

In Vitro Metabolism of Mirtazapine Enantiomers by Human Cytochrome P450 Enzymes: **S. Dodd, D. W. Boulton, G. D. Burrows, C. L. DeVane and T. R. Norman** 541

Book Reviews 545

Erratum
The Pharmacokinetics of THC in Fat and Brain: Resulting Functional Responses to Marihuana Smoking: **G. G. Nahas** 549

Current Awareness 551

Issue No.8 December 2001

THE HUMAN PSYCHOPHARMACOLOGY OF MDMA OR 'ECSTASY'
Editor: A. C. Parrott

Review
Human Psychopharmacology of Ecstasy (MDMA): A Review of 15 Years of Empirical Research: **A. C. Parrott** 557

Research Articles
Investigating the Potential Neurotoxicity of Ecstasy (MDMA): An Imaging Approach: **L. Reneman, J. Booij, C. B. L. M. Majoie, W. van den Brink and G. J. den Heeten** 579

Which Neuroreceptors Mediate the Subjective Effects of MDMA in Humans? A Summary of Mechanistic Studies: **M. E. Liechti and F. X. Vollenweider** 589

Ecstasy Abuse and Dependence among Adolescents and Young Adults: Applicability and Reliability of DSM-IV Criteria: **L. B. Cottler, S. B. Womack, W. M. Compton and A. Ben-Abdallah** 599

Prospective Memory, Everyday Cognitive Failure and Central Executive Function in Recreational Users of Ecstasy: **T. M. Heffernan, H. Jarvis, J. Rodgers, A. B. Scholey and J. Ling** 607

Auditory Verbal Learning in Drug-Free Ecstasy Polydrug Users: **H. C. Fox, A. S. Toplis, J. J. D. Turner and A. C. Parrott** 613

Differential Effects of Ecstasy and Cannabis on Self-Reports of Memory Ability: A Web-Based Study: **J. Rodgers, T. Buchanan, A. B. Scholey, T. M. Heffernan, J. Ling and A. Parrott** 619

Psychological Profile of Abstinent Recreational Ecstasy (MDMA) Users and Significance of Concomitant Cannabis Use: **J. Daumann, S. Pelz, S. Becker, F. Tuchtenhagen and E. Gouzoulis-Mayfrank** . . 627

Personality Dimensions and Psychopathological Profiles of Ecstasy Users: **G. Dughiero, F. Schifano and G. Forza** 635

Psychiatric Disorders in Ecstasy (MDMA) Users: A Literature Review Focusing on Personal Predisposition and Drug History: **K. Soar, J. J. D. Turner and A. C. Parrott** 641

Current Awareness 647

Author Index 657

Keyword Index 659

Volume Contents i

Supplement No.2 December 2001

THE ENANTIOMER DEBATE:
REALISING THE POTENTIAL OF ENANTIOMERS IN PSYCHOPHARMACOLOGY
Editors: J. Caldwell and B. E. Leonard

An Introduction to the 'Enantiomer Debate': **J. Caldwell and B. E. Leonard** S65

Do Single Enantiomers Have Something Special to Offer?: **J. Caldwell** S67

The Therapeutic Promise of Single Enantiomers: Introduction: **I. W. Wainer** S73

An Introduction to Enantiomers in Psychopharmacology: **B. E. Leonard** S79

Enantiomeric Antidepressant Drugs Should Be Considered on Individual Merit: **P. Baumann and C. B. Eap** S85

Unmet Needs in the Pharmacological Management of Depression: **D. S. Baldwin** S93

The Enantiomer Debate: Current Status and Future Directions: **I. Hindmarch** S101

Stereochemistry: Definitions and a Note on Nomenclature: **J. Caldwell and I. W. Wainer** S105